NCT07127510Recruiting
Brain NAD in Alzheimer's Disease
Measurement of Brain NAD Levels in Alzheimer's Patients and Control Subjects by 1H-MRS
Source: ClinicalTrials.gov · Last updated 24 Mar 2026
Brief summary (registry, in English)
The goal of this observational study is to learn about the levels of nicotinamide adenine dinucleotide (NAD) in the brains of people with Alzheimer's disease. The study aims to determine if brain NAD levels are lower in people with Alzheimer's disease compared with people of the same age group who do not have Alzheimer's disease. Participants with or without Alzheimer's disease will have a brain imaging session where NAD will be measured using magnetic resonance spectroscopy (MRS). Eight months later, they will have a second, similar, brain imaging session.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 20 (estimated)
- First submitted
- 11 Aug 2025
- Start date
- 18 Mar 2026
- Primary completion date
- 1 Apr 2027
- Lead sponsor
- Florida Atlantic University
- Diseases
- Alzheimer disease
- NCT number
- NCT07127510
What you commit to
- Study type: Observational
- Planned participants: 20
- From 18 Mar 2026 to the primary completion date, 1 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Receiving anti-amyloid intravenous treatments Leqembi or Kinsula.
Other illness
- Advanced dementia such that the person would require sedation for undergoing an MRI scan.
- Having a history of seizures.
- Having cancer or having been diagnosed with cancer within the last 5 years (excluding superficial squameous or basal cell cancer).
Age
- Under the age of 65 or over the age of 80.
Other
- Having an MRI-incompatible pacemaker or other MRI-incompatible hardware (e.g. comprising a metallic part).
- Working at night.
- People with no AD: MoCA test result lower than 26.
Who the study is looking for
- Participants are able to come to the Florida Atlantic University Clinical Research Unit, are verbal and ambulatory.
- Age 65 to 80 included.
- People with Alzheimer's disease (AD): AD diagnosis established by the person's physician according to the following criteria: clinical diagnosis AND either positive amyloid PET-scan or FDA-approved positive CSF or blood test.
Age in the registry: 65 years to 80 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| FAU Clinical Research Unit Coordinator of this site? Confirm its status | Boca Raton | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.